期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

嵌合抗原受体修饰免疫细胞治疗肿瘤的新策略 被引量：2

New strategies of tumor therapy by using chimeric antigen receptor-modified immunocyte
原文传递
导出
摘要 以嵌合抗原受体(CAR)为基础的细胞免疫治疗目前成为治疗恶性肿瘤的一种新兴形式。CAR技术的应用在以下几方面受到密切关注:选择合适的目标抗原;甄选高效、安全的基因转导方法;优化信号分子;筛选最具潜质的免疫细胞。随着研究的深入和技术的提高,相信CAR技术会给肿瘤患者带来福音。 Chimeric antigen receptor- （CAR-） based immunotherapy has been an emerging therapeutic modality for malignant tumor. It attracts close attention on choosing appropriate target antigen, filtering efficient and safe genetic modification, optimizing signal molecules, selecting good therapeutic immune cells and so on. It is believed that CAR will bring promising news to cancer patients, as the researches continue and the techniques improve.
作者 胡婉丽 赵嫄 张连生
机构地区 兰州大学第二医院血液科
出处 《中华临床医师杂志（电子版）》 CAS 2014年第6期127-130,共4页 Chinese Journal of Clinicians(Electronic Edition)
关键词 肿瘤 免疫疗法 嵌合抗原受体 Neoplasms lmmunotherapy Chimeric antigen receptor
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Ramos CA, Dotti G. Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J]. Expert Opin Biol Ther, 2011, 11(7): 855-873.
  • 2Goldberger O, Volovitz I, Maehlenkin A, et al. Exuberated numbers of tumor- specific T cells result in tumor escape[J]. Cancer Res, 2008, 68: 3450-3457.
  • 3Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLAA2-restrieted, EBNA3C-specific chimeric antigen receptor[J]. Cancer Gene Ther, 2012, 19(2): 84-99.
  • 4Stewart-Jones G, Wadle A, Hombach A, et al. Rational development of highaffinity T-cell receptor-like antibodies[J]. Proc Nail Acad Sci U S A, 2009, 106(14): 5784-5788.
  • 5Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy[J]. Leuk Lymphoma, 1995, 18(5/6): 385-397.
  • 6Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydmse IX: first clinical experience[J]. J Clin Oncol, 2006, 24(13): e20-e22.
  • 7Lamers CH, Willemsen R, van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells[J]. Blood, 2011, 117(1): 72-82.
  • 8Casucei M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen reeaptor-rodirected T lymphocytes[J]. J Cancer, 2011, 2(1): 378-382.
  • 9Lamers CH, Willemsen RA, van Elzakker P, et al. Phoenix-ampho outperforms PG13 as retroviral packaging ceils to transducer human T cells with tumor-specific recap tors : implications for clinical immunogene therapy of cancer[J]. Cancer Gene Ther, 2006, 13(5): 503-509.
  • 10Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration[J]. Nat Biotechnol, 2006,24(6): 687-696.

二级参考文献28

  • 1Ramos CA, Dotti G. Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J]. Expert Opin Biol Ther, 2011, 11(7): 855-873.
  • 2Goldberger O, Volovitz I, Maehlenkin A, et al. Exuberated numbers of tumor- specific T cells result in tumor escape[J]. Cancer Res, 2008, 68: 3450-3457.
  • 3Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLAA2-restrieted, EBNA3C-specific chimeric antigen receptor[J]. Cancer Gene Ther, 2012, 19(2): 84-99.
  • 4Stewart-Jones G, Wadle A, Hombach A, et al. Rational development of highaffinity T-cell receptor-like antibodies[J]. Proc Nail Acad Sci U S A, 2009, 106(14): 5784-5788.
  • 5Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy[J]. Leuk Lymphoma, 1995, 18(5/6): 385-397.
  • 6Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydmse IX: first clinical experience[J]. J Clin Oncol, 2006, 24(13): e20-e22.
  • 7Lamers CH, Willemsen R, van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells[J]. Blood, 2011, 117(1): 72-82.
  • 8Casucei M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen reeaptor-rodirected T lymphocytes[J]. J Cancer, 2011, 2(1): 378-382.
  • 9Lamers CH, Willemsen RA, van Elzakker P, et al. Phoenix-ampho outperforms PG13 as retroviral packaging ceils to transducer human T cells with tumor-specific recap tors : implications for clinical immunogene therapy of cancer[J]. Cancer Gene Ther, 2006, 13(5): 503-509.
  • 10Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration[J]. Nat Biotechnol, 2006,24(6): 687-696.

共引文献1

同被引文献32

  • 1Ramos CA, Dotti G. Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J]. Expert Opin Biol Ther, 2011, 11(7): 855-873.
  • 2Goldberger O, Volovitz I, Maehlenkin A, et al. Exuberated numbers of tumor- specific T cells result in tumor escape[J]. Cancer Res, 2008, 68: 3450-3457.
  • 3Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLAA2-restrieted, EBNA3C-specific chimeric antigen receptor[J]. Cancer Gene Ther, 2012, 19(2): 84-99.
  • 4Stewart-Jones G, Wadle A, Hombach A, et al. Rational development of highaffinity T-cell receptor-like antibodies[J]. Proc Nail Acad Sci U S A, 2009, 106(14): 5784-5788.
  • 5Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy[J]. Leuk Lymphoma, 1995, 18(5/6): 385-397.
  • 6Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydmse IX: first clinical experience[J]. J Clin Oncol, 2006, 24(13): e20-e22.
  • 7Lamers CH, Willemsen R, van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells[J]. Blood, 2011, 117(1): 72-82.
  • 8Casucei M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen reeaptor-rodirected T lymphocytes[J]. J Cancer, 2011, 2(1): 378-382.
  • 9Lamers CH, Willemsen RA, van Elzakker P, et al. Phoenix-ampho outperforms PG13 as retroviral packaging ceils to transducer human T cells with tumor-specific recap tors : implications for clinical immunogene therapy of cancer[J]. Cancer Gene Ther, 2006, 13(5): 503-509.
  • 10Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration[J]. Nat Biotechnol, 2006,24(6): 687-696.

引证文献2

二级引证文献2

中华临床医师杂志（电子版）
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部